One of the most important additions to our therapeutic agents during recent years is the series of preparations from the suprarenal gland. While we do not yet know how widely these preparations may be used with satisfactory results, we do know that their value as therapeutic agents is such that they are depended on in many conditions, and that they should, therefore, be of uniform quality and character. The reports1 which we published two weeks ago of the experimental work on these preparations show very plainly that the preparations on the market are of variable quality and character. This must not be. There is probably as much need for the standardization of these preparations as there is for the standardization of other organo-therapeutic products, such as diphtheria antitoxin, vaccine virus, etc. It is perfectly practicable to determine the strength of these suprarenal preparations with accuracy and to standardize them.
STANDARDIZATION OF SUPRARENAL PRODUCTS. JAMA. 1906;XLVII(12):944. doi:10.1001/jama.1906.02520120040009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: